Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s share price passed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $7.26 and traded as high as $7.65. Eupraxia Pharmaceuticals shares last traded at $7.42, with a volume of 567,278 shares trading hands.
Analyst Ratings Changes
EPRX has been the topic of a number of research analyst reports. Wedbush initiated coverage on Eupraxia Pharmaceuticals in a report on Thursday, September 24th. They set an "outperform" rating and a $17.00 target price on the stock. Stifel Nicolaus set a $25.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Sunday. Oppenheimer reissued an "outperform" rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, October 20th. Finally, HC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $17.17.
Read Our Latest Stock Analysis on Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Stock Up 7.7%
The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $498.92 million, a PE ratio of -7.27 and a beta of 1.04. The business's 50 day simple moving average is $7.56 and its 200 day simple moving average is $7.26.
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. As a group, analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.90 EPS for the current year.
Institutional Trading of Eupraxia Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its holdings in shares of Eupraxia Pharmaceuticals by 28.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company's stock valued at $133,000 after acquiring an additional 3,500 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in Eupraxia Pharmaceuticals in the 2nd quarter worth approximately $25,000. AXQ Capital LP lifted its holdings in Eupraxia Pharmaceuticals by 34.2% in the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company's stock worth $140,000 after purchasing an additional 5,390 shares during the last quarter. BlackRock Inc. bought a new stake in Eupraxia Pharmaceuticals during the second quarter worth approximately $40,000. Finally, Bank of America Corp DE boosted its position in Eupraxia Pharmaceuticals by 5.9% during the first quarter. Bank of America Corp DE now owns 268,221 shares of the company's stock worth $1,942,000 after purchasing an additional 14,900 shares during the period.
About Eupraxia Pharmaceuticals
(
Get Free Report)
Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.
Eupraxia's lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
